BRAF and neoplasm: Although our two patient sets were small, which is a limitation, the results demonstrate the prognostic relevance of CD8+ and FOXP3+ T cells, tumor proliferation rate and BRAF mutation status, and support the concept that several factors in combination predict prognosis in stage III CMM better than single markers.